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Abstract
PURPOSE: To assess the hemostatic responses to exercise in a patient with
Polycythemia Vera (PV). METHODS: Six female runners (≥15 miles/week) completed a
maximal treadmill test. One subject had PV while the other five subjects made up the
comparison group. Blood samples were taken before and within two minutes after
exercise. VO2max was also recorded. RESULTS: Pre-exercise Factor VIII and tPAantigen were similar in the PV subject and comparison group. Factor VIII and tPAantigen increased dramatically in the PV subject (+100%, +1000%) in relation to the
comparison group (+22.9 ± 8.7%, +108 ± 78%) after exercise. Pre-exercise PAI-1 was
lower in the PV subject and also decreased slightly more (-100%) in response to exercise
than the comparison group (-43 ± 67%). CONCLUSIONS: Factor VIII, tPA-antigen, and
PAI-1 responses to exercise are more dramatic in a Polycythemia Vera patient than in
those without the disorder.
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Chapter I: Introduction
Polycythemia Vera is a rare myeloproliferative neoplasm in which the bone
marrow produces too many blood cells due to a mutation within the bone marrow. Red
blood cells are mainly affected, however an overproduction of platelets and leukocytes
may also be associated with this blood disorder. The most prevalent mutation is in the
protein JAK2, which plays a role in cell growth. The JAK2 V617F mutation is seen in
95% of cases. Polycythemia is mainly diagnosed in males over age 60, however the
disorder may occur at any age in both males and females. The incidence rate for this
disorder in females aged 20-34 years is .04 per 100,000.6 Risks associated with
Polycythemia include thrombotic events such as blood clots and ischemia, splenomegaly,
and progression to other blood disorders.12 Simple treatments for mild cases consist of
phlebotomies to maintain hematocrit between 40-45% and a daily 81 mg aspirin.18 Since
this disorder is very uncommon, especially for young people, there is a lack of research
on the subject.
Polycythemia Vera increases the risk for blood clots due to high hematocrit levels
and a possible high number of platelets, which creates more viscous blood. Although
high hematocrit levels have not been proven to be a direct cause for thrombotic events,
previous studies have found strong correlations between hematocrit level and clot risk.17
The Tromsø study recruited 13714 women and 12394 men as subjects in 1994-5. After
12.5 years of follow-up, 447 venous thromboembolic events had occurred within the
sample population. Compared to an age-adjusted hazard ratio of 1.0 for hematocrit <39%
in women and <43% in men, the hazard ratio for unprovoked VTE with hematocrit ≥42%
in women and ≥46% in men was 1.62 and 2.37, respectively.4 During exercise,
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hematocrit levels increase due to a loss of plasma volume13; therefore, risks associated
with high hematocrit levels in those with Polycythemia Vera may be exacerbated if
combined with exercise.
In addition to increasing blood viscosity by increasing hematocrit, exercise also
independently alters hemostasis by acutely increasing coagulation potential and
fibrinolysis.10 Markers of coagulation potential that increase with exercise include
Thrombin anti-thrombin3, Factor VIII2, and platelet activation8. Fibrinolytic potential is
also increased during acute exercise as evidenced by increases in tissue plasminogen
activator (tPA) activity11 and a decrease in the main circulating inhibitor of tPA,
plasminogen activator inhibitor (PAI-1). tPA-antigen also increases in proportion to tPA
activity during exercise15. Although markers of fibrinolysis increase along with markers
of coagulation potential, fibrinolysis decreases at a faster rate in the post-exercise
period14, which thereby increases potential for thrombosis. Thus, a multitude of variables
can contribute to clotting risks during and after exercise that may lead to life-threatening
ischemic events. This increased risk for the general population may be enhanced in a
person with polycythemia vera. Since this disorder is typically seen in older male
populations, little to no research exists on the complications of exercise in a young,
active, female with polycythemia vera. This lack of research is most likely due to the
minimal amount of available subjects and the reduced ability of the elderly with
Polycythemia Vera to perform strenuous exercise.
A previous study simulated Polycythemia by infusion of erythrocytes (60%
hematocrit) in 5 heat-acclimated male subjects and analyzed the effects of hydration and
exercise on thermoregulation. Each subject completed four heat stress tests: pre and post-
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infusion in a euhydrated state and pre and post-infusion in a hypohydrated state. The heat
stress tests consisted of two trials of a 45-minute walk with a 15-minute rest in a hot (35
degrees C and 45% humidity) environment. Interestingly, simulated Polycythemia Vera
resulted in a thermoregulatory advantage in both a euhydrated and hypohydrated state as
post-infusion responses increased sweating rate, decreased core body temperature, and
increased plasma volume.16 However, because this study simply increased RBC count in
otherwise healthy people, the comparative exercise response in people who have the
chronic form of Polycythemia is unknown. Polycythemia Vera may consist of elevated
platelet counts in addition to high hematocrit and in turn may cause different hemostatic
responses than solely erythrocyte injection. Exercise acutely increases platelet activation,
which may be intensified with the presence of an increased platelet count. Therefore, the
simulated Polycythemia study may not be representative of the chronic polycythemia
population. Rather, this study supported the thermoregulatory advantages of blood
doping. Thus, there is a paucity of research on exercise responses in patients with
Polycythemia Vera.
Understanding the risks associated with Polycythemia is important in relation to
exercise and other environments that increase thrombosis. Further information is
necessary in determining the magnitude of these risks, as blood clots are a serious
medical condition that can lead to other complications such as heart attacks and strokes.12
Since the increased risks with Polycythemia may be unavoidable, it is important to gather
information on the responses to exercise. The purpose of this study is to create new
information and analyze the effects of Polycythemia Vera on clotting factors after
exercise in a young female diagnosed with Polycythemia compared to subjects without
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the blood disorder. Further knowledge about this topic may lead to other remedies and
prevention strategies in an effort to reduce the symptoms and risk factors associated with
Polycythemia Vera.
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Chapter II: Methods
Participants: The subjects in this study will consist of 10 college-aged, female runners
(self-reporting >15 miles per week). The student researcher will be participating as the
Polycythemia Vera subject, while the other subjects will be healthy adults without
Polycythemia Vera. All subjects will be informed of the procedures and will give
informed consent to participate. Subjects will be recruited by word of mouth around JMU
and the greater Harrisonburg area. Participants will be at least 18 years of age. Deception
will not be used among the participants in this study.
Exercise Testing: Prior to testing, all subjects will start this research study by being
assigned an appropriate amount of fluid to ingest per day (42.9mL/kg of body weight) for
a week.5 Following the week of controlled hydration, each subject will run an
incremental treadmill test in a controlled environment between 7 and 9 a.m. The treadmill
test will begin at 2.5 mph and increase 0.5 mph every minute until 6.0 mph; the speed
will then remain constant as the grade increases by 3% every minute until volitional
exhaustion. Oxygen uptake will be monitored using a metabolic cart and a heart rate
monitor will be used to gather heart rate data.

Blood sampling, assays: Prior to the treadmill test, participants will rest in a semirecumbant position for 15 minutes. Following this rest period, 10 mL of blood will be
drawn from an antecubital vein using assumed venipuncture. All blood samples will be
obtained by either Dr. Womack or a student/faculty member that’s been appropriately
trained via procedures approved by the Human Performance Laboratory. The protocol
for becoming trained and approved for venipuncture is listed in Appendix C. Samples
12

will be obtained in an identical manner (except for the 15 minute rest period)
immediately post-exercise. Hematocrit and hemoglobin levels will be measured from the
whole blood samples using a Hemocue automated analyzer. The remainder of the blood
samples will be centrifuged immediately for 20 minutes at 1,500xg and 4C to obtain
platelet-poor plasma, and then frozen and stored at -20C until assayed. Plasma
concentrations of factor VIII levels, tPA-antigen, and PAI-1 activity will be determined
using commercially available ELISA kits (VisuLize® Ontario, Canada; Eagle
Bioscience, Inc, Nashua, New Hampshire) according to manufacturer specifications.

Risks/Benefits: With strenuous activity, there is potential for muscle or joint soreness,
and a slight risk of more serious muscular or cardiovascular injury such as muscle strain
or sprain, ligament damage, heart attack or stroke. The overall risk of strenuous activity
(including both low- and high-risk participants) is approximately six cardiac events per
10,000 tests, or 0.06%. The risk of a complication requiring hospitalization (including
non-cardiac problems) is ≤ 0.2%. Risks of blood drawing may include discomfort,
bruising, and, in rare instances, infection, lightheadedness, and fainting. In order to
mitigate these exercise related risks, participants will be screened with a health-history
questionnaire. Only low risk participants, based on the American College of Sports
Medicine guidelines, will be included in the study. Furthermore, all faculty and students
engaged in exercise testing in the Human Performance Laboratory are required to have
current CPR training. Any evidence of an acute cardiovascular event will prompt the
research team to activate emergency medical services by calling 911.
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Alternatives to participating in the study: All participants will be informed that they have
the right to withdraw from the study at any time without penalty.

Benefits of Research: Due to the limited existing research on Polycythemia Vera, this
study may provide initial information for further research on the risks of exercise in this
specific population. Participants will also be given information regarding their
cardiorespiratory fitness from the exercise test.

Research will take place at the Human Performance Lab in Godwin Hall located on the
campus of James Madison University. Research will be completed within the Fall
semester of 2016 (by December 16th, 2016, after receiving IRB approval).

Data Collection: Data will originally be collected on paper data sheets and then will be
manually entered into a computer spreadsheet. Data, including a flash drive with the
spreadsheet, will be locked in a file cabinet in Dr. Womack’s office. Dr. Womack and I
will be the only people to have access to the data. All consent forms will be kept in a
separate file in a locked file cabinet in Dr. Womack’s office. Dr. Womack will be the
only one with access to said file cabinet. All subjects will be given a subject # which will
be used as an identifier on all data sheets during the study. The key for the ID numbers
will be kept in the same file as the consent forms. Data will be destroyed by Dr. Womack
within a year after my completed honor’s thesis.
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Reporting Procedures: The audience to be reached in the report of this study is the
Honor’s thesis committee and the Honor’s college. Research will be presented to the
Department of Kinesiology faculty and students and a possible regional/local exercise
science conference.

The subjects will receive feedback from the study via email.

Data Analysis
Due to the limited sample size, this study will be treated as a pilot study and will be
analyzed without statistical comparisons. Hematocrit and clotting factors will be
compared between each subject before and after exercise. The differences in clotting
factors between the control subjects will then be compared to the differences in the
Polycythemia Vera subject.

Experience of the Researcher (and advisor, if student):
Dr. Christopher J Womack, PhD will be advising me through my first research
experience with this study. Dr. Womack has over 25 years of research experience and has
authored or co-authored over 50 papers in peer-reviewed exercise science journals. He is
a Fellow of the American College of Sports Medicine, the governing body that
establishes Guidelines for Exercise Testing and Prescription.
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Chapter III: Manuscript
Introduction
Polycythemia Vera is a rare myeloproliferative neoplasm in which the bone
marrow produces too many blood cells due to a mutation within the bone marrow. Red
blood cells are mainly affected, however an overproduction of platelets and leukocytes
may also be associated with this blood disorder. The incidence rate for this disorder in
females aged 20-34 years is 0.04 per 100,000.6 Risks associated with Polycythemia
include thrombotic events such as blood clots and ischemia, splenomegaly, and
progression to other blood disorders.21 Simple treatments for mild cases consist of
phlebotomies to maintain hematocrit between 40-45% and a daily 81 mg aspirin.29 Since
this disorder is very uncommon, especially for young people, there is a lack of research
on the subject.
Although high hematocrit levels have not been proven to be a direct cause for
thrombotic events, previous studies have found strong correlations between hematocrit
level and clot risk.27 During exercise, hematocrit levels increase due to a loss of plasma
volume20; therefore, risks associated with high hematocrit levels in those with
Polycythemia Vera may be exacerbated if combined with exercise. In addition to
increasing blood viscosity by increasing hematocrit, exercise also independently alters
hemostasis by acutely increasing coagulation potential and fibrinolysis.16 Markers of
coagulation potential that increase with exercise include Thrombin anti-thrombin4, Factor
VIII2, and platelet activation.12 Fibrinolytic, or clot lysis, potential is also increased
during acute exercise as evidenced by increases in tissue plasminogen activator (tPA)
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activity18 and a decrease in the main circulating inhibitor of tPA, plasminogen activator
inhibitor (PAI-1). tPA-antigen also increases in proportion to tPA activity during
exercise.25 Although markers of fibrinolysis increase along with markers of coagulation
potential, fibrinolysis decreases at a faster rate in the post-exercise period24, which
thereby increases potential for thrombosis. Thus, a multitude of variables can contribute
to clotting risks during and after exercise that may lead to life-threatening ischemic
events. This increased risk for the general population may be enhanced in a person with
Polycythemia Vera due to the elevated number of platelets activated by exercise.14 Since
this disorder is typically seen in older male populations, little to no research exists on the
complications of exercise in a young, active, female with Polycythemia Vera. This lack
of research is most likely due to the minimal amount of available subjects and the
reduced ability of the elderly with Polycythemia Vera to perform strenuous exercise.
A previous study simulated Polycythemia Vera by infusion of erythrocytes (60%
hematocrit) in five heat-acclimated male subjects. Interestingly, simulated Polycythemia
Vera resulted in a thermoregulatory advantage in both a euhydrated and hypohydrated
state as post-infusion responses increased sweating rate, decreased core body
temperature, and increased plasma volume.26 However, because this study simply
increased RBC count in otherwise healthy people, the comparative exercise response in
people who have the chronic form of Polycythemia is unknown. Polycythemia Vera may
consist of elevated platelet counts in addition to high hematocrit and in turn may cause
different hemostatic responses than solely erythrocyte injection. Exercise acutely
increases platelet activation, which may be intensified with the presence of an increased
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platelet count. Therefore, the simulated Polycythemia study may not be representative of
the chronic Polycythemia population.
Understanding the risks associated with Polycythemia is important in relation to
exercise and other environments that increase thrombosis. Further information is
necessary to determine the magnitude of these risks, as blood clots are a serious medical
condition that can lead to other complications such as heart attacks and strokes.12 Since
the increased risks with Polycythemia may be unavoidable, it is important to gather
information on the responses to exercise. The purpose of this study is to create new
information and analyze the effects of Polycythemia Vera on clotting factors after
exercise in a young female diagnosed with Polycythemia compared to subjects without
the blood disorder. Further knowledge about this topic may lead to other remedies and
prevention strategies in an effort to reduce the symptoms and risk factors associated with
Polycythemia Vera.
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Methods
Participants: The subjects in this study consisted of 6 college-aged, female runners (selfreporting >15 miles per week). The student researcher participated as the Polycythemia
Vera subject, while the other subjects in the control group were healthy adults without
Polycythemia Vera. The control group had a mean height, weight, and VO2max of 168.4
± 7.9 cm, 67.2 ± 11.0 kg, and 43.2 ± 4.3 ml/kg/min respectively. Mean age for the control
group was 21 years. The Polycythemia Vera subject’s height, weight, and VO2max were
165.1 cm, 55.8 kg, and 60 ml/kg/min. The Polycythemia Vera subject was 21 years old.
All subjects were informed of the procedures and gave informed consent to participate.
Subjects were recruited by word of mouth around JMU and the greater Harrisonburg
area.
Exercise Testing: Prior to testing, all subjects were assigned an appropriate amount of
fluid to ingest per day (42.9mL/kg of body weight) for a week.9 Following the week of
controlled hydration, each subject ran an incremental treadmill test in a controlled
environment between 8 and 10 a.m. The treadmill test began at 2.5 mph and increased 0.5
mph every minute until 6.0 mph; the speed then remained constant as the grade increased
by 3% every minute until volitional exhaustion. Oxygen uptake was monitored using a
Moxus metabolic cart and a heart rate monitor was used to gather heart rate data. All
subjects were fasted for a minimum of 10 hours prior to testing and abstained from
alcohol 24 hours prior to testing.

Blood sampling, assays: Prior to the treadmill test, participants rested in a semirecumbant position for 15 minutes. Following this rest period, 10 mL of blood was
drawn from an antecubital vein using assumed venipuncture. Samples were obtained in
19

an identical manner (except for the 15 minute rest period) immediately post-exercise.
Hematocrit and hemoglobin levels were measured from the whole blood samples using a
Hemocue automated analyzer. The remainder of the blood samples were centrifuged
immediately for 20 minutes at 1,500xg and 4C to obtain platelet-poor plasma, and then
frozen and stored at -20C until assayed. Plasma concentrations of factor VIII levels,
tPA-antigen, and PAI-1 activity were determined using commercially available ELISA
kits (VisuLize® Ontario, Canada; Eagle Bioscience, Inc, Nashua, New Hampshire)
according to manufacturer specifications.
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Results

The comparison group completed the maximal treadmill test with a mean
VO2max of 43.2 ± 4.3 ml/kg/min while the Polycythemia Vera (PV) subject achieved a
VO2max of 60 ml/kg/min. Pre- and Post-exercise hemostatic variables for the PV patient
and the comparison group are displayed in Table 1. The comparison group had a mean
pre-exercise hematocrit and hemoglobin of 40.5 ± .8% and 13.38 ± .97 g/dl respectively.
Pre-exercise hematocrit and hemoglobin in the PV patient was 44.5% and 15.15 g/dl.
Hematocrit in both groups increased in response to exercise similarly. Hemoglobin in the
PV subject increased less (+6.9%) than the comparison group (+11.51 ± 1.42%) after
exercise. The PV subject’s pre-exercise Factor VIII (0.64) was similar to the comparison
group pre-exercise (0.70 ± 0.11). However, the PV subject had a larger increase (+100%)
than the comparison group following exercise (+22.9 ± 8.7%). Pre-exercise tPA-antigen
was similar in the PV subject (1.1) and the comparison group (1.00 ± 0.31). Post-exercise
tPA-antigen in the PV subject increased dramatically (+1000%) relative to the
comparison group (+108 ± 78%). Pre-exercise PAI-1 was lower in the PV subject (0.56)
than the comparison group (3.21 ± 2.22). Post-exercise PAI-1 in the PV subject had a
larger decrease (-100%) than subjects in the comparison group (-43 ± 67%).
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Table 1. Mean (±SD) for all hemostatic variables for the Polycythemia Vera patient and the
comparison group.
Variable
Polycythemia Vera Patient
Comparison Group (mean ±
SD)
Factor VIII
Pre-Exercise
.64
.70 ± .11
Post-Exercise
1.28
.86 ± .19
% change with
100%
22.9 ± 8.7%
exercise
tPA-antigen
Pre-Exercise
1.13
1.00 ± .31
Post-Exercise
12.50
2.08 ± .86
% change with
1000%
108 ± 78%
exercise
PAI-1
Pre-Exercise
0.55
3.21 ± 2.22
Post-Exercise
0
1.83 ± 1.60
% change with
-100%
-43 ± 67%
exercise
Hematocrit
Pre-Exercise
44.5
40.5 ± .8
Post-Exercise
47.5
43.8 ± 2.2
% change with
6.7%
8.15 ± .57%
exercise
Hemoglobin
Pre-Exercise
15.15
13.38 ± .97
Post-Exercise
16.2
14.92 ± .76
% change with
6.9%
11.51 ± 1.42%
exercise
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Discussion
Hematocrit
As expected, the Polycythemia Vera subject started with higher pre-exercise
hematocrit levels than the control group. Hematocrit increased in the Polycythemia
subject at a similar degree to the control group in response to exercise. While artificially
increasing hematocrit (e.g. blood doping) has resulted in enhanced aerobic performance,
naturally occurring elevated hematocrit levels may have a negative effect on aerobic
fitness.5, 6 A study of 77 soccer players in France separated each player into specific
quintiles based on their hematocrit. The first quintile contained those with the lowest
hematocrit (38.7 ± .8) while the 5th quintile contained players with the highest hematocrit
(45.5 ± .3). The 2nd, 3rd, and 4th quintiles contained players with a mean hematocrit of
42.3 ± .2. The players in the 1st quintile proved to have a higher aerobic fitness level than
the players in every other quintile, thus suggesting an inverse relationship between
hematocrit and fitness. This inverse relationship may be attributable to a hemodilution
effect associated with training. Ferritin also has a negative correlation with hematocrit,
which could be a factor contributing to a lower aerobic fitness level in those with high
hematocrit.5 Patients with Polycythemia Vera typically have lower ferritin levels30 and
therefore, the higher VO2max achieved by the Polycythemia Vera subject may not be due
to a high hematocrit.
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Factor VIII
Pre-exercise Factor VIII levels for both the Polycythemia Vera subject and
control group were similar. The Polycythemia Vera subject’s post-exercise levels
exhibited a larger increase than the control group. This may be explained by the higher
intensity and duration of exercise achieved by the Polycythemia Vera subject.1 There is
also speculation of a chronically activated coagulation cascade in patients with
Polycythemia Vera, specifically the intrinsic pathway.8 Factor VIII is an intrinsic
pathway factor that originates from platelets.3 With the combination of a chronically
activated intrinsic pathway and elevated levels of platelets associated with Polycythemia
Vera, an increased production or activation of Factor VIII could be associated with these
Polycythemia Vera complications.

tPA antigen
tPA-antigen in the Polycythemia Vera subject was similar to the control group
before exercise. Post-exercise tPA-antigen, however, increased dramatically in the
Polycythemia Vera subject compared to the control group. Although tPA is positively
correlated with exercise intensity28 and may explain a portion of the greater increase, the
large difference between groups would suggest other mechanisms contributing to the
marked increase observed in the Polycythemia Vera patient.
Along with increased red blood cells, Polycythemia Vera may also be
accompanied with elevated platelet levels. In Polycythemia Vera patients with the
JAK2V617F mutation, platelet thrombin generation potential was significantly elevated
compared to control groups.23 Exercise also enhances thrombin generation, which can
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lead to platelet activation.17 With an increased presence of thrombin and activated
platelets, clot formation may increase due to the conversion of fibrinogen to fibrin.11
Since fibrin is necessary for the creation of plasmin by tissue plasminogen activator22,
tPA-antigen may be more susceptible to increase during exercise in Polycythemia Vera
patients.

PAI-1
Pre-exercise PAI-1 in the Polycythemia Vera subject was lower than the control
group, which contradicts previous findings of elevated PAI-1 in Polycythemia Vera
subjects.7 PAI-1 can also be significantly influenced by BMI. Although the protocol did
not collect BMI specifically, the Polycythemia Vera subject had the lowest BMI
calculated from height and weight. In agreement with previous research, a lower BMI
correlates with lower PAI-1.31

Implications
Since high Factor VIII levels may increase risk for thrombotic events15, 19, a low PAI-1
level may be important in attenuating these risks. The high tPA-antigen response to
exercise in the Polycythemia Vera subject may represent increased fibrinolytic response
to offset the increased coagulation potential evidenced during exercise. High Factor VIII
in response to exercise increases the risk for thrombosis and other related events,
however the large increase in post-exercise tPA-antigen may be able to attenuate these
risks. Since fibrinolysis tends to decrease at a faster rater than coagulation potential,
Polycythemia Vera patients may be at an increased risk for thrombotic events after
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exercise due to a larger production of Factor VIII, however the dramatically high tPAantigen response may have an acute protective affect during and immediately after
exercise. Extensive research must be conducted before these findings can be generalized
to the whole Polycythemia Vera population. Future research is also necessary on this
disorder in order to find effective treatment during exercise. The current treatment for
mild Polycythemia Vera is a daily 81mg aspirin and phlebotomy p.r.n., however previous
research indicates aspirin may not be effective in the context of exercise.13

Limitations:
There are many limitations to these findings since this study only included one
Polycythemia Vera subject. Perhaps researching subjects with similar VO2max and BMI
values may have led to more comparable results. The mean results in the control group
also do not have any statistical significance due to the small sample size.
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Consent to Participate in Research
Identification of Investigators & Purpose of Study
You are being asked to participate in a research study conducted by Allison Huschke
and Christopher J. Womack, Ph.D. from James Madison University. The purpose of
this study is to determine if a person with Polycythemia Vera is more likely to have
higher clotting potential after exercise than a healthy adult without the blood
disorder.

Potential Risks & Benefits
If you choose to participate in this study, you will perform one maximal treadmill
test. With strenuous exercise, the investigator perceives a potential for muscle or
joint soreness, and a slight risk of more serious muscular or cardiovascular injury
such as muscle strain or sprain, ligament damage, heart attack or stroke. In healthy
individuals, the risk of death during vigorous exercise has been estimated at 1 death
per year for every 18,000 individuals. In order to mitigate these exercise related
risks, participants will be screened with a health-history questionnaire. Only low
risk participants, based on the American College of Sports Medicine guidelines, will
be included in the study. Furthermore, all faculty and students engaged in exercise
testing in the Human Performance Laboratory are required to have current CPR
training. Any evidence of an acute cardiovascular event will prompt the research
team to activate emergency medical services by calling 911.
Potential benefits from participation in this study include:
VO2max results and the opportunity to help increase research conducted on Polycythemia
Vera.

Research Procedures
Should you decide to participate in this research study, you will be asked to sign this
consent form once all your questions have been answered to your satisfaction. This
study consists of one week of controlled hydration as well as one maximal treadmill
test. You will also be subjected to blood tests both before and after each trial. Your
heart rate will be monitored by a monitor that wraps around your chest.
Blood Sampling: We will obtain about 10 ml of blood (about 2 teaspoons) prior to
and immediately after the treadmill test in order to determine the potential of your
blood to coagulate. These blood samples will be obtained from an arm vein.

Confidentiality
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The results of this study will be presented to the Department of Kinesiology faculty
and students and a possible regional/local exercise science conference. The results
of this project will be coded in such a way that your identity will not be attached to
the final form of this study. The researcher retains the right to use and publish nonidentifiable data. However, you can ask that your data be removed from the study at
any point prior to presentation and publication. While individual responses are
confidential, aggregate data will be presented representing averages or
generalizations about the responses as a whole. All data will be stored in a secure
location accessible only to the researchers. Data will be destroyed within a year
after research is completed. Final results will be made available to you upon
request.

Participation & Withdrawal
Your participation is entirely voluntary. You are free to choose not to participate.
Should you choose to participate, you can withdraw at any time without
consequences of any kind. Your right to withdraw includes the right to request that
your blood samples be discarded at any time.

Questions
You may have questions or concerns during the time of your participation in this
study, or after its completion. If you have any questions about the study, contact
Allison Huschke at huschkam@dukes.jmu.edu, or Christopher J. Womack, Ph.D. at
womackcx@jmu.edu or 540-568-6515.

Giving of Consent
I have read this consent form and I understand what is being requested of me as a
participant in this study. I freely consent to participate. I have been given
satisfactory answers to my questions. The investigator provided me with a copy of
this form. I certify that I am at least 18 years of age.

Name of Participant (Printed)

Name of Researcher(s) (Printed)

Name of Participant (Signed)

Name of Researcher(s) (Signed)

Date

Date
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For questions about your rights as a research subject, you may contact the chair of
JMU’s Institutional Review Board (IRB). Dr. David Cockley, (540) 568-2834,
cocklede@jmu.edu.
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James Madison University
Department of Kinesiology
Health Status Questionnaire
Instructions: Complete each question accurately. All information provided is
confidential.
Part I: General Information
1. Subject #
2. Local Phone
Email:
____________________________________
3. Gender (circle one) Male Female
4. Date of Birth (Month/ Day/ Year)
Part II: Medical History
5. Circle any that died of heart attack before age 50: Father Mother Brother
Sister Grandparent

6. Date of last medical exam: _____________ Last physical fitness test:
_______________
7. Circle operations you have had: Back Heart Kidney Eyes
Ears Hernia
Lung

Joint

Neck

Other ________________

8. Please circle any of the following for which you have been diagnosed or
treated by a physician or health professional:
Alcoholism
Diabetes
Anemia (sickle cell) Emphysema
Anemia (other)
Epilepsy
Asthma
Eye Problems
Back Strain
Gout
Bleeding trait
Hearing Loss
Bronchitis, chronic Heart Problem
Cancer
High Blood Pressure
Cirrhosis, liver
Hypoglycemia
Concussion
Hyperglycemia
Congenital defect
Infectious Mononucleosis
Other _____________________
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Kidney Problems
Mental Illness
Muscular Injury
Neck Strain
Obesity
Orthopedic Injuries
Phlebitis
Rheumatoid arthritis
Stroke
Thyroid problem
Ulcer

9. Circle all medications taken in the last six months:
Blood thinner
Diabetic pill
Digitalis
Diuretic

Epilepsy medication
Nitroglycerin
Heart-rhythm medication
Other __________________
High-blood pressure medication
Insulin

10. Any of these health symptoms that occur frequently is the basis for medical
attention. Circle the
number indicating how often you have each of the following:
5 = Very often 4 = Fairly often 3 = Sometimes 2 = Infrequently 1=
Practically never
a. cough up blood
1 2 3 4 5

f. chest pain
1 2 3 4 5

b. abdominal pain
1 2 3 4 5

g. swollen joints
1 2 3 4 5

c. low back pain
1 2 3 4 5

h. feel faint
1 2 3 4 5

d. leg pain
1 2 3 4 5

i. dizziness
1 2 3 4 5

e. arm or shoulder pain
1 2 3 4 5

j. breathless on slight exertion
1 2 3 4 5

Part III: Health Related Behavior
11. Do you smoke? Yes No
12. If you are a smoker, indicate the number of smoked per day:
Cigarettes:
40 or more

20-39

10-19

1-9

Cigars or pipes only:
5 or more or any inhaled less than 5, none inhaled
13. Do you exercise regularly? Yes No
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14. How many times in a week do you spend at least 30 minutes in moderate to
strenuous/vigorous
exercise?
1

2

3

4

5

6

7

days per week

15. Can you walk 4 miles briskly without fatigue? Yes No
16. Can you jog 3 miles continuously at a moderate pace without discomfort?
Yes
No
17. Weight now: __________ lb. One year ago: __________ lb Age 21:
__________ lb
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PROCEDURES/POLICIES FOR VENOUS BLOOD DRAWS
Laboratory faculty, instructors and researchers (including research assistants)
should complete the following training actions prior to conducting this procedure:
a) Complete all standard lab safety procedures (review CHBS Lab Safety Plan and the HPL
Safety Protocols and Responsibilities, and complete the Acknowledgement of Safety
Training Form and HPL Safety Protocols Test)
b) Compete bloodborne pathogen training (http://www.jmu.edu/bbp/index.shtml)
c) Review the written procedures below
d) Receive hands-on training from a trained faculty member (or graduate student who has
completed training previously), including at least three consecutive successful procedures
by the trainee
e) Complete/sign page 2 of this form, and provide a hard-copy to the Lab Director
(Dr. Mike Saunders)

Procedures
1) Prepare all materials ahead of time: needle, plastic Vacutainer holder (screw
needle into holder ahead of time, and leave cover on needle), rubber
tourniquet, alcohol swabs, gauze, Vacutainer tubes.
2) Exam gloves are to be worn at all times
3) Subject will have the needle inserted in an antecubital vein while sitting in a
partially reclined chair.
4) Apply tourniquet firmly to arm around the lower bicep area.
5) Palpate the area on the inside of the elbow joint to find a prominent
anticubital vein.
6) Prepare the insertion area by wiping thoroughly with an alcohol swab, then
allow ~30 seconds for any remaining alcohol to evaporate.
7) Remove cover from needle and insert the needle (beveled edge facing up)
through the skin into the anticubital vein, along the center of the longitudinal
axis of the vein.
8) Once the needle is in the vein, hold the plastic needle holder steady, and
press the Vacutainer firmly into the plastic holder (puncturing the seal on the
Vacutainer, and initiating blood collection).
9) Remove tourniquet as the Vacutainer is filling.
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10)Once the desired amount of blood is obtained, remove the Vacutainer from
the holder (if you are filling more than one tube, insert a second tube as
described in # 8).
11)To remove the needle from the vein, quickly withdraw the needle in a
direction directly opposite to insertion. Immediately apply sterile gauze to
the area and apply pressure.
12)Have the subject continue to apply pressure to the area for at least 2 minutes
to cease bleeding and prevent bruising.
13)Apply a band-aid over top of the gauze.
14)Waste removal:
a. All sharps (needles, catheter, any glass, hard plastic, etc) must be
disposed in a red plastic sharps container (Biohazard).
b. All non-sharps materials that have been in contact (or potentially in
contact) with blood (gauze, gloves, etc.) must be disposed in a red
Biohazard bag.
c. Unsoiled paper wrappers etc. can be disposed in regular trash bins.
d. Check that all waste has been removed, and the area is entirely clear
of any waste/blood.
e. If any blood has spilled in the area (i.e. on chairs, floor, equipment),
clean thoroughly with germicidal bleach (i.e. Clorox®) and paper
towels.
f. If you are supervising students who are performing this technique (i.e.
for a lab class or study), it is your responsibility to double-check the
area is clean before leaving the area.

Date of Training Completion:
By signing below, the Trainee is acknowledging that they have completed
items a, b, c, and d on page 1 of this form. The Trainer is acknowledging
that they have provided hands-on training of this procedure for the
Trainee, and have witnessed the trainee perform the procedures
successfully on at least three consecutive occasions.
Trainee (individual completing the training):
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Name

Signature

Date

Trainer (individual providing the training):

Name

Signature
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Date
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